Institute of Experimental Physiology, Faculty of Biochemical and Pharmaceutical Sciences, Rosario National University, Suipacha 570, 2000 Rosario, Argentina.
Institute of Experimental Physiology, Faculty of Biochemical and Pharmaceutical Sciences, Rosario National University, Suipacha 570, 2000 Rosario, Argentina; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
Pharmacol Res. 2021 Jan;163:105251. doi: 10.1016/j.phrs.2020.105251. Epub 2020 Oct 13.
The extensive intestinal surface offers an advantage regarding nutrient, ion and water absorptive capacity but also brings along a high exposition to xenobiotics, including drugs of therapeutic use and food contaminants. After absorption of these compounds by the enterocytes, apical ABC transporters play a key role in secreting them back to the intestinal lumen, hence acting as a transcellular barrier. Rapid and reversible modulation of their activity is a subject of increasing interest for pharmacologists. On the one hand, a decrease in transporter activity may result in increased absorption of therapeutic agents given orally. On the other hand, an increase in transporter activity would decrease their absorption and therapeutic efficacy. Although of less relevance, apical ABC transporters also contribute to disposition of drugs systemically administered. This review article summarizes the present knowledge on the mechanisms aimed to rapidly regulate the activity of the main apical ABC transporters of the gut: multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 2 (MRP2) and breast cancer resistance protein (BCRP). Regulation of these mechanisms by drugs, drug delivery systems, drug excipients and nutritional components are particularly considered. This information could provide the basis for controlled regulation of bioavailability of therapeutic agents and at the same time would help to prevent potential drug-drug interactions.
肠道的巨大表面积使其在营养物质、离子和水分吸收能力方面具有优势,但也使它更容易受到包括治疗药物和食物污染物在内的外源性物质的影响。进入肠上皮细胞的这些化合物,由顶端 ABC 转运体将它们分泌回肠腔,从而发挥细胞间屏障的作用。因此,这些转运体的活性的快速和可逆调节是药理学研究的热点。一方面,转运体活性的降低可能导致经口给予的治疗药物的吸收增加。另一方面,转运体活性的增加会降低其吸收和治疗效果。尽管相关性较小,但顶端 ABC 转运体也有助于全身给予的药物的处置。本文综述了目前关于快速调节肠道主要顶端 ABC 转运体(多药耐药蛋白 1(MDR1)、多药耐药相关蛋白 2(MRP2)和乳腺癌耐药蛋白(BCRP))活性的机制的知识。特别考虑了这些机制受药物、药物传递系统、药物赋形剂和营养成分的调节。这些信息可以为治疗药物生物利用度的控制调节提供基础,同时有助于预防潜在的药物相互作用。